Leerink Partners analyst Puneet Souda maintained a Buy rating on Centogene NV (CNTG – Research Report) on March 30 and set a price target of $10.00. The company's shares closed last Thursday at $4.21, close to its 52-week low of $3.16. According to TipRanks.com, Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.0% and a 40.9% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience. Centogene NV has an analyst consensus of Moderate Buy, with a price target consensus of $12.00, a 194.1% upside from current levels.
https://www.tipranks.com/news/blurbs/leerink-partners-thinks-centogene-nvs-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral